1-8 of 8
Federico Cappuzzo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial

Federico Cappuzzo, Biagio Ricciuti, Angelo Delmonte, Laura Bonanno, Xiaoyue Wang, Weng Kit Lye, Andreas Görtz, Kalliopi Andrikou, Alessandro Dal Maso, Gabriele Minuti, Maximilian Papi, Joao Victor Alessi, Alessandro Di Federico, Scott Rodig, Mark Magdi Awad, Giulio Metro, Ilaria Attili, Fabiana Vitiello, Sara Pilotto, Stefania Gori, Giulio Rossi, Simonetta Buglioni, Diana Giannarelli, Lorenza Landi
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (6): 1027–1036.
https://doi.org/10.1158/1078-0432.CCR-24-2077
Published: 17 March 2025
View article titled, MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Open the PDF for MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial in another window
Includes: Supplementary data
Journal Articles

Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy

Stefano Scalera, Biagio Ricciuti, Daniele Marinelli, Marco Mazzotta, Laura Cipriani, Giulia Bon, Giulia Schiavoni, Irene Terrenato, Alessandro Di Federico, Joao V. Alessi, Maurizio Fanciulli, Ludovica Ciuffreda, Francesca De Nicola, Frauke Goeman, Giulio Caravagna, Daniele Santini, Ruggero De Maria, Federico Cappuzzo, Gennaro Ciliberto, Mariam Jamal-Hanjani, Mark M. Awad, Nicholas McGranahan, Marcello Maugeri-SaccĂ 
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4397–4411.
https://doi.org/10.1158/1078-0432.CCR-24-0626
Published: 01 October 2024
View article titled, Transcriptional Phenocopies of Deleterious <em>KEAP1</em> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Open the PDF for Transcriptional Phenocopies of Deleterious <em>KEAP1</em> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Crizotinib in ROS1 and MET Deregulated NSCLC—Response

Lorenza Landi, Rossella Bruno, Gabriella Fontanini, Federico Cappuzzo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (7): 1775.
https://doi.org/10.1158/1078-0432.CCR-20-0026
Published: 01 April 2020
View article titled, Crizotinib in <em>ROS1</em> and <em>MET</em> Deregulated NSCLC—Response
Open the PDF for Crizotinib in <em>ROS1</em> and <em>MET</em> Deregulated NSCLC—Response in another window
Journal Articles

Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

Lorenza Landi, Rita Chiari, Marcello Tiseo, Federica D'IncĂ , Claudio Dazzi, Antonio Chella, Angelo Delmonte, Laura Bonanno, Diana Giannarelli, Diego Luigi Cortinovis, Filippo de Marinis, Gloria Borra, Alessandro Morabito, Cesare Gridelli, Domenico Galetta, Fausto Barbieri, Francesco Grossi, Enrica Capelletto, Gabriele Minuti, Francesca Mazzoni, Claudio Verusio, Emilio Bria, Greta AlĂŹ, Rossella Bruno, Agnese Proietti, Gabriella Fontanini, Lucio CrinĂČ, Federico Cappuzzo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (24): 7312–7319.
https://doi.org/10.1158/1078-0432.CCR-19-0994
Published: 13 December 2019
View article titled, Crizotinib in <em>MET</em>-Deregulated or <em>ROS1</em>-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Open the PDF for Crizotinib in <em>MET</em>-Deregulated or <em>ROS1</em>-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial in another window
Includes: Supplementary data
Journal Articles

HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan?

Federico Cappuzzo, Lorenza Landi
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (11): 2470–2472.
https://doi.org/10.1158/1078-0432.CCR-18-0198
Published: 31 May 2018
View article titled, <em>HER2</em> Deregulation in Lung Cancer: Right Time to Adopt an Orphan?
Open the PDF for <em>HER2</em> Deregulation in Lung Cancer: Right Time to Adopt an Orphan? in another window
Journal Articles

Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

Kurtis D. Davies, Anh T. Le, Mariana F. Theodoro, Margaret C. Skokan, Dara L. Aisner, Eamon M. Berge, Luigi M. Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli, Marco Alloisio, Armando Santoro, D. Ross Camidge, Marileila Varella-Garcia, Robert C. Doebele
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4570–4579.
https://doi.org/10.1158/1078-0432.CCR-12-0550
Published: 30 August 2012
View article titled, Identifying and Targeting <em>ROS1</em> Gene Fusions in Non–Small Cell Lung Cancer
Open the PDF for Identifying and Targeting <em>ROS1</em> Gene Fusions in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer

Rafal Dziadziuszko, Samir E. Witta, Federico Cappuzzo, Seongjin Park, Koji Tanaka, Peter V. Danenberg, Anna E. Barón, Lucio Crino, Wilbur A. Franklin, Paul A. Bunn, Jr., Marileila Varella-Garcia, Kathleen D. Danenberg, Fred R. Hirsch
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (10): 3078–3084.
https://doi.org/10.1158/1078-0432.CCR-06-0106
Published: 17 May 2006
View article titled, Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer
Open the PDF for Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer in another window
Journal Articles

Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer

Vanesa Gregorc, Giovanni Luca Ceresoli, Irene Floriani, Anna Spreafico, Katia Bruna Bencardino, Vienna Ludovini, Lorenza Pistola, Zhasmina Mihaylova, Francesca Romana Tofanetti, Massimiliano Ferraldeschi, Valter Torri, Federico Cappuzzo, Lucio Crinò, Maurizio Tonato, Eugenio Villa
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6006–6012.
https://doi.org/10.1158/1078-0432.CCR-03-0770
Published: 24 September 2004
View article titled, Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer
Open the PDF for Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer in another window